Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Capable and willing to provide written informed consent or assent~* Documented diagnosis of PH1 or PH2, confirmed by genotyping~* Must meet the 24 hour urine oxalate excretion requirements~* Less than 20% variation between the two 24-hour urinary creatinine excretion values derived from the two 24-hour urine collections in the screening period~* Estimated GFR at screening ≥ 30 mL/min normalized to 1.73 m2 BSA~Key Exclusion Criteria:~* Renal or hepatic transplantation (prior or planned within the study period)~* Currently on dialysis or anticipated requirement for dialysis during the study period~* Plasma oxalate \>30 µmol/L~* Documented evidence of clinical manifestations of systemic oxalosis (including pre-existing retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations)~* Use of an RNA interference (RNAi) drug within the last 6 months~* Participation in any clinical study in which you received an investigational medicinal product (IMP) within 4 months before Screening~* Liver function test (LFT) abnormalities: Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>1.5 times upper limit of normal (ULN) for age and gender~* Inability or unwillingness to comply with study procedures

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCR-PHXC (Type: EXPERIMENTAL): Intervention, drug, DCR-PHXC
- Placebo - Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): Placebo, sterile normal saline (0.9% NaCl) for subcutaneous (SC) injection

Based on this trial design, predict the completion outcome and termination type (if applicable).